Literature DB >> 20687228

Glycemic control and prostate cancer progression: results from the SEARCH database.

Howard S Kim1, Joseph C Presti, William J Aronson, Martha K Terris, Christopher J Kane, Christopher L Amling, Stephen J Freedland.   

Abstract

PURPOSE: Several studies have examined the association between diabetes mellitus (DM) and prostate cancer (PCa) risk and progression, however nearly all of these studies have compared diabetic versus non-diabetic men. We sought to investigate the role of glycemic control, as measured by HbA1c, on PCa aggressiveness and prognosis in men with DM and PCa from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
METHODS: We identified 247 men in SEARCH with DM and a recorded HbA1c value within the 12 months prior to radical prostatectomy between 1988 and 2009. We divided these men into tertiles by HbA1c level. The associations between HbA1c tertiles and risk of adverse pathology and biochemical recurrence were tested using multivariate logistic regression and Cox proportional hazards models, respectively.
RESULTS: Median HbA1c level was 6.9. On multivariate analysis, HbA1c tertiles were predictive of pathological Gleason score (P-trend = 0.001). Relative to the first tertile, men in the second (OR 4.68, P = 0.003) and third tertile (OR 6.60, P < 0.001) were more likely to have Gleason score > or = 4 + 3. HbA1c tertiles were not associated with margin status, node status, extracapsular extension or seminal vesicle invasion (all P-trend > 0.2). In the multivariate Cox proportional hazards model, increasing HbA1c tertiles were not significantly related to risk of biochemical recurrence (P-trend = 0.56).
CONCLUSION: Men with higher HbA1c levels presented with more biologically aggressive prostate tumors at radical prostatectomy. Although risk of recurrence was unrelated to HbA1c levels, further studies are needed to better explore the importance of glycemic control on long-term outcomes in diabetic men with PCa. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20687228      PMCID: PMC2930134          DOI: 10.1002/pros.21189

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  23 in total

1.  Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy.

Authors:  Takashi Imamoto; Hiroyoshi Suzuki; Satoshi Fukasawa; Masaki Shimbo; Masahiko Inahara; Akira Komiya; Takeshi Ueda; Taizo Shiraishi; Tomohiko Ichikawa
Journal:  Eur Urol       Date:  2004-12-29       Impact factor: 20.096

2.  History of diabetes, clinical features of prostate cancer, and prostate cancer recurrence-data from CaPSURE (United States).

Authors:  J M Chan; D M Latini; J Cowan; J Duchane; P R Carroll
Journal:  Cancer Causes Control       Date:  2005-09       Impact factor: 2.506

3.  Diabetes mellitus and risk of colorectal cancer: a meta-analysis.

Authors:  Susanna C Larsson; Nicola Orsini; Alicja Wolk
Journal:  J Natl Cancer Inst       Date:  2005-11-16       Impact factor: 13.506

4.  Diabetes mellitus and prostate cancer risk.

Authors:  Brandon L Pierce; Stephen Plymate; Elaine A Ostrander; Janet L Stanford
Journal:  Prostate       Date:  2008-07-01       Impact factor: 4.104

5.  Significance of preoperative HbA1c level in patients with diabetes mellitus and clinically localized prostate cancer.

Authors:  Sung Kyu Hong; Seung Tae Lee; Sung Soo Kim; Kyung Eun Min; Seok-Soo Byun; Sung Yong Cho; Gheeyoung Choe; Sang Eun Lee
Journal:  Prostate       Date:  2009-06-01       Impact factor: 4.104

6.  Hormonal profile of diabetic men and the potential link to prostate cancer.

Authors:  Jocelyn S Kasper; Yan Liu; Michael N Pollak; Nader Rifai; Edward Giovannucci
Journal:  Cancer Causes Control       Date:  2008-03-14       Impact factor: 2.506

Review 7.  Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis.

Authors:  Eric L Ding; Yiqing Song; Vasanti S Malik; Simin Liu
Journal:  JAMA       Date:  2006-03-15       Impact factor: 56.272

8.  Diabetes mellitus and risk of breast cancer: a meta-analysis.

Authors:  Susanna C Larsson; Christos S Mantzoros; Alicja Wolk
Journal:  Int J Cancer       Date:  2007-08-15       Impact factor: 7.396

9.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

10.  Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis.

Authors:  J Everhart; D Wright
Journal:  JAMA       Date:  1995 May 24-31       Impact factor: 56.272

View more
  17 in total

1.  Diabetes mellitus is associated with short prostate-specific antigen doubling time after radical prostatectomy.

Authors:  Jong Jin Oh; Sung Kyu Hong; Sangchul Lee; Seung June Sohn; Sang Eun Lee
Journal:  Int Urol Nephrol       Date:  2012-09-29       Impact factor: 2.370

2.  Poorly controlled diabetes increases the risk of metastases and castration-resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH database.

Authors:  Farnoosh Nik-Ahd; Lauren E Howard; Adva T Eisenberg; William J Aronson; Martha K Terris; Matthew R Cooperberg; Christopher L Amling; Christopher J Kane; Stephen J Freedland
Journal:  Cancer       Date:  2019-04-29       Impact factor: 6.860

Review 3.  Epithelial cancers in the post-genomic era: should we reconsider our lifestyle?

Authors:  Jeff M P Holly; Li Zeng; Claire M Perks
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

Review 4.  Meta-analysis of metabolic syndrome and prostate cancer.

Authors:  M Gacci; G I Russo; C De Nunzio; A Sebastianelli; M Salvi; L Vignozzi; A Tubaro; G Morgia; S Serni
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-02-21       Impact factor: 5.554

5.  Randomized trial evaluating the role of weight loss in overweight and obese men with early stage prostate Cancer on active surveillance: Rationale and design of the Prostate Cancer Active Lifestyle Study (PALS).

Authors:  Jeannette M Schenk; Marian L Neuhouser; Sarah J Beatty; Matthew VanDoren; Daniel W Lin; Michael Porter; John L Gore; Roman Gulati; Stephen R Plymate; Jonathan L Wright
Journal:  Contemp Clin Trials       Date:  2019-04-16       Impact factor: 2.226

6.  Hyperglycemia and prostate cancer recurrence in men treated for localized prostate cancer.

Authors:  J L Wright; S R Plymate; M P Porter; J L Gore; D W Lin; E Hu; S B Zeliadt
Journal:  Prostate Cancer Prostatic Dis       Date:  2013-03-05       Impact factor: 5.554

7.  Tumor features and survival after radical prostatectomy among antidiabetic drug users.

Authors:  R M Joentausta; P M Kujala; T Visakorpi; T L J Tammela; T J Murtola
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-08-09       Impact factor: 5.554

8.  Testosterone Deficiency is Not Protective Against the Development of Adenocarcinoma of the Prostate in a Type 1 Diabetic Patient.

Authors:  David S H Bell; Terri Jerkins
Journal:  Diabetes Ther       Date:  2022-04-07       Impact factor: 3.595

9.  Inflammatory cytokines and survival factors from serum modulate tweak-induced apoptosis in PC-3 prostate cancer cells.

Authors:  Ana Belen Sanz; Maria Dolores Sanchez-Niño; Susana Carrasco; Felix Manzarbeitia; Olga Ruiz-Andres; Rafael Selgas; Marta Ruiz-Ortega; Carmen Gonzalez-Enguita; Jesus Egido; Alberto Ortiz
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

10.  Vitamin d levels in subjects with prostate cancer compared to age-matched controls.

Authors:  Subhashini Yaturu; Sonya Zdunek; Barbara Youngberg
Journal:  Prostate Cancer       Date:  2012-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.